BridgeMD
New treatment option for Hepatocellular Carcinoma, Scirrhous
Official title HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma
ClinicalTrials.gov ID: NCT04499833
What this study is testing
- What it's testing
- Liver transplant is the most effective treatment for hepatocellular carcinoma (HCC) in cirrhosis. Due to organs shortage, the proper selection of patients is imperative.
- Time commitment: about 60 months
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Hepatocellular carcinoma associated with cirrhosis
- Ages between 18 and 70 years
- Total tumour volume below 500 cm3
- Total number of tumour lesions below 10
- Maximum individual tumour diameter below 10 cm
You likely can't join if
- eligible under the "Milan Criteria"
The study team makes the final eligibility decision.
Where it's taking place
- Lisbon, Portugal
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 60 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lisbon, Portugal. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.